Dr David Lim and Associate Professor Neale Cohen discuss why GPs need to be aware of potential heart complications in patients with T2DM.
- In this era of SGLT2 inhibitors and GLP1 agonists, we need to initiate these therapies early because of their cardioprotective and renoprotective (for SGLT2I) benefits
- The incidence of heart failure, silent ischaemia and arrhythmias are higher in patients with T2DM and GPs need a high index of suspicion to identify, diagnose and treat these
Host: Dr David Lim, GP and medical educator
Guest: Associate Professor Neale Cohen, endocrinologist; Director of clinical diabetes, the Baker Heart and Diabetes Institute, Melbourne
Total time: 27 mins